AC Immune SA vs Curis
Curis is the larger business, with $9.4m of revenue in fiscal 2025 against $4.3m for AC Immune SA (2.2 times as much). Curis grew faster (-13.4% against -86.1%). Curis kept more of each dollar of sales as profit: a net margin of -80.3% against -1971.6%. AC Immune SA carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | AC Immune SAACIU, 2025 | CurisCRIS, 2025 |
|---|---|---|
| Revenue | $4.3m | $9.4m |
| Revenue growth | -86.1% | -13.4% |
| Net income | −$85.0m | −$7.6m |
| Operating margin | -1940.1% | -60.5% |
| Net margin | -1971.6% | -80.3% |
| Return on equity | -94.3% | — |
| Free cash flow | −$84.7m | −$27.2m |
| Cash | $33.8m | $5.1m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 24 |
| Market value | $213m | $1.4m |
| Price vs our value range | — | — |
| Moat score | — | 8 (Weak) |
| Insider trades, 12 months | 1 buys, 2 sales | 1 buys, 0 sales |